Cost-Efectiveness of Delayed-Release Dimethyl Fumarate Compared to Glatiramer Acetate and Fingolimod for the Treatment of Relapsing-Remiting Multiple Sclerosis

Mauskopf, J., Fay, M., Iyer, R., & Livingston, T. (2014). Cost-Efectiveness of Delayed-Release Dimethyl Fumarate Compared to Glatiramer Acetate and Fingolimod for the Treatment of Relapsing-Remiting Multiple Sclerosis. Value in Health, 17(3), A60-A61.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
Article

Use of a web-based portal to return normal individual research results in Early Check
Article

The importance of quality data to track global progress in addressing stillbirths and neonatal mortality